HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

IRX4204

retinoid X receptor (RXR) agonist; structure in first source

Networked: 3 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Cyclopropanes: 9
        IRX4204: 3

Experts

1.	Aguilar, Ethan G: 2 articles (01/2022 - 01/2021)
2.	Blazar, Bruce R: 2 articles (01/2022 - 01/2021)
3.	Panoskaltsis-Mortari, Angela: 2 articles (01/2022 - 01/2021)
4.	Thangavelu, Govindarajan: 2 articles (01/2022 - 01/2021)
5.	Noelle, Randolph J: 2 articles (01/2021 - 01/2016)
6.	Du, Jing: 1 article (01/2022)
7.	Flynn, Ryan: 1 article (01/2022)
8.	Mohamed, Fathima A: 1 article (01/2022)
9.	Rhee, Stephanie Y: 1 article (01/2022)
10.	Riddle, Megan J: 1 article (01/2022)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2022 - "In this study, we evaluated the efficacy of IRX4204, a novel agonist that activates RXRs and is in clinical trials for cancer treatment to prevent and treat cGVHD in two complementary murine models. "
2.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/01/2016 - "Furthermore in a murine model of multiple sclerosis (experimental autoimmune encephalomyelitis (EAE)), treatment with IRX4204 profoundly attenuates both active and Th17-mediated passive disease. " 01/01/2016 - "Treatment with retinoid X receptor agonist IRX4204 ameliorates experimental autoimmune encephalomyelitis."
3.	Graft vs Host Disease (Graft-Versus-Host Disease) 01/01/2021 - "In this study, in vivo IRX4204 compared favorably with FK506 in abrogating acute graft-versus-host disease (GVHD), which was associated with inhibiting allogeneic donor T-cell proliferation, reducing T-helper 1 differentiation, and promoting regulatory T-cell (Treg) generation. "
4.	Multiple Sclerosis 01/01/2016 - "Furthermore in a murine model of multiple sclerosis (experimental autoimmune encephalomyelitis (EAE)), treatment with IRX4204 profoundly attenuates both active and Th17-mediated passive disease. "
5.	Bronchiolitis Obliterans 01/01/2022 - "Together, these results indicate that IRX4204 is a promising therapeutic option to treat cGVHD with bronchiolitis obliterans or sclerodermatous manifestations." 01/01/2022 - "In a major histocompatibility complex mismatched, non-sclerodermatous multiorgan system model with bronchiolitis obliterans, IRX4204 prevented and reversed cGVHD including associated pulmonary dysfunction with restoration of germinal center T-follicular helper: T-follicular regulatory cell balance. "

Related Drugs and Biologics

1.	Retinoid X Receptors (Retinoid X Receptor)
2.	Tacrolimus (Prograf)